Reviewed by Michael Gill, B. Sc.
7 Hydrocephalus Clinical Trials Near Me
Top Hospitals for Hydrocephalus Clinical Trials
Image of Yale University in Connecticut.
Yale University
New Haven
2Active Trials
2All Time Trials for Hydrocephalus
2022First Hydrocephalus Trial
Image of University at Buffalo, in New York.
University at Buffalo,
Buffalo
1Active Trials
1All Time Trials for Hydrocephalus
2022First Hydrocephalus Trial
Top Cities for Hydrocephalus Clinical Trials
Image of New York in New York.
New York
3Active Trials
NYU Langone HealthTop Active Site
Image of New Haven in Connecticut.
New Haven
2Active Trials
Yale UniversityTop Active Site
Hydrocephalus Clinical Trials by Phase of Trial
Phase 1 Hydrocephalus Clinical Trials
1Active Hydrocephalus Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Hydrocephalus Clinical Trials by Age Group
< 18 Hydrocephalus Clinical Trials
1Active Hydrocephalus Clinical Trials
Top Treatments for Hydrocephalus Clinical Trials
Treatment Name
Active Hydrocephalus Clinical Trials
All Time Trials for Hydrocephalus
First Recorded Hydrocephalus Trial
Device Arm
1
1
2022
eShunt Implant
1
2
2022
Open Shunt Group
1
1
2022
long term prophylactic antibiotics
1
1
2021
Hyperfine MRI scan
1
1
2019

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991. https://pubmed.ncbi.nlm.nih.gov/158170192 Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. https://pubmed.ncbi.nlm.nih.gov/306266263 Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5). pii: neurintsurg-2021-018136. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. https://pubmed.ncbi.nlm.nih.gov/348622674 Welk B, Lenherr S, Elliott S, Stoffel J, Gomes CM, de Bessa J, Cintra LKL, Myers JB; Neurogenic Bladder Research Group. The creation and validation of a short form of the Neurogenic Bladder Symptom Score. Neurourol Urodyn. 2020 Apr;39(4):1162-1169. doi: 10.1002/nau.24336. Epub 2020 Mar 20. https://pubmed.ncbi.nlm.nih.gov/321967325 Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014 Aug;192(2):452-7. doi: 10.1016/j.juro.2014.01.027. Epub 2014 Feb 8. https://pubmed.ncbi.nlm.nih.gov/24518764